Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro

Frontiers in Oncology(2020)10.3389/fonc.2020.00700Source: DataRank Database

Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro is a research paper published in Frontiers in Oncology (2020). On theSindex it has a DataRank of 0. It has been cited 41 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access41 citations

Download PDF

Cite:

Linked data & code

nct pdb doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 2.36)OA: goldTopics (33)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Ning Ji ORCID,Qiu‐Xu Teng,Chao‐Yun Cai,Jing‐Quan Wang ORCID,Zhuo‐Xun Wu

Live enrichment

PubMed:32477943 PMC:PMC7236772 OpenAlex:https://openalex.org/W3024878521

National Institutes of Health

Grant: 1R15GM116043-01

Nanowaveguide Illuminated Fluorescence Spectroscopy for Studying Membrane Protein Dynamics

National Institutes of Health

FWCI

2.36

Citation Percentile

0.9%

Citation Trend

2019

2020

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://doi.org/10.3389/fonc.2020.00700

publisherhttps://doi.org/10.3389/fonc.2020.00700

publisherhttps://www.frontiersin.org/article/10.3389/fonc.2020.00700/full

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32477943

repositoryhttps://doaj.org/article/e647cab029494c2e9c81fb9b02933cba

Fields of Study

Drug Transport and Resistance MechanismsCancer therapeutics and mechanismsMetal complexes synthesis and properties0301 basic medicine0303 health sciences03 medical and health sciences

Keywords

Abcg2Tyrosine-kinase inhibitorATP-binding cassette transporterPharmacologyEffluxMultiple drug resistanceTyrosine kinaseMTT assayTransporterDaunorubicinIn vitroChemistryBiologyCancer researchBiochemistryCancerSignal transductionLeukemiaGeneMultidrug resistanceTyrosine kinase inhibitorAtp-binding Cassette (Abc) TransportersSitravatinibAtp-binding Cassette Super-family G Member 2 (Abcg2)OncologyNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells in vitro

FAIR Checklist

Authors (10)

Funding (2 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)